Loading...

NTHI NEONC TECHNOLOGIES HOLDINGS INC Company Mergers 8-K Filing

NNC

NTH

NEONC TECHNOLOGIES HOLDINGS INC

(NTHI)

2025 8-K

Financial Results Report

Share Issuance Update

Management Change

Clinical Trial Update

Legal Settlement Reached

Securities Offering

Investor Conference Planned

Stock Sale Agreement

Clinical Results Update

New Shares Issued

Management Changes

Clinical Results Update

Investor Conference Call

Management Change

Strategic Partnership

Service Agreement Signed

FDA Trial Approval

Acquisition Announcement

Financial Restatement

Financial Restatement

Research Grants Awarded

Asset Acquisitions

Debt-Equity Swaps

External Links:

On September 10, 2025, NeOnc Technologies Holdings, Inc. announced FDA authorization to advance to Phase IIa/IIb of its NEO212-01 clinical trial, marking a significant step in their research.

AI Assistant

NEONC TECHNOLOGIES HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.